Novocure Initiates Usability Study for Flexible Torso Array
Novocure (NASDAQ: NVCR) today announced it has advanced a new, flexible torso array into a clinical usability study.
- Novocure (NASDAQ: NVCR) today announced it has advanced a new, flexible torso array into a clinical usability study.
- Novocure designed the array to improve patient comfort for all torso and abdominal indications.
- Novocure plans to conclude the usability study in the third quarter of 2021 and will identify the preferred regulatory pathway to bring the updated, flexible array to patients as soon as possible.
- Our investment in the flexible array reflects our commitment to increase the ease-of-use of our products and to help patients increase their time-on-therapy and quality-of-life.